Maheshi N Ramasamy
Overview
Explore the profile of Maheshi N Ramasamy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
6235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Handunnetthi L, Ramasamy M, Turtle L, Hunt D
Nat Rev Neurol
. 2024 Aug;
20(9):541-554.
PMID: 39112653
Vaccines protect against many infectious diseases, including some that can directly or indirectly cause nervous system damage. Serious neurological consequences of immunization are typically extremely rare, although they have the...
2.
Williams L, Emary K, Phillips D, Hay J, Larwood J, Ramasamy M, et al.
Vaccine
. 2024 Jul;
42(21):126167.
PMID: 39060202
Background: For pathogens which cause infections that present asymptomatically, evaluating vaccine efficacy (VE) against asymptomatic infection is important for understanding a vaccine's potential epidemiological impact. Regular testing for subclinical infections...
3.
Clemens S, Jepson B, Bhorat Q, Ahmad A, Akhund T, Aley P, et al.
Lancet Microbe
. 2024 Jun;
5(8):100863.
PMID: 38878794
Background: AZD2816 is a variant-adapted COVID-19 vaccine that expresses the full-length SARS-CoV-2 beta variant spike protein but is otherwise similar to AZD1222 (ChAdOx1 nCoV-19). This study aimed to evaluate the...
4.
Raman B, Ramasamy M
Lancet Infect Dis
. 2023 Dec;
24(3):219-221.
PMID: 38071991
No abstract available.
5.
Baqar S, Bonavia A, Louis Bourgeois A, Campo J, Clifford A, Hanevik K, et al.
Vaccine
. 2023 Nov;
42(7):1445-1453.
PMID: 38036392
The global public health nonprofit organization PATH hosted the third Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference in Washington, DC, from November 29 to December 1, 2022. This...
6.
Skidmore P, Canals R, Ramasamy M
Expert Rev Vaccines
. 2023 Oct;
22(1):918-920.
PMID: 37824701
No abstract available.
7.
Ramasamy M, Kelly E, Seegobin S, Dargan P, Payne R, Libri V, et al.
Lancet Microbe
. 2023 Oct;
4(11):e863-e874.
PMID: 37783221
Background: This study aimed to evaluate AZD2816, a variant-updated COVID-19 vaccine expressing the full-length SARS-CoV-2 beta (B.1.351) variant spike protein that is otherwise similar to AZD1222 (ChAdOx1 nCoV-19), and AZD1222...
8.
McCann N, Emary K, Singh N, McLean F, Camara S, Jones E, et al.
BMJ Open
. 2023 May;
13(5):e068966.
PMID: 37225278
Introduction: This is the first efficacy study of an oral live attenuated vaccine against Paratyphi A using a human challenge model of paratyphoid infection. . Paratyphi A is responsible for...
9.
Shaw R, Greenland M, Stuart A, Aley P, Andrews N, Cameron J, et al.
J Infect
. 2023 Apr;
86(6):574-583.
PMID: 37028454
Background: Heterologous COVID vaccine priming schedules are immunogenic and effective. This report aims to understand the persistence of immune response to the viral vectored, mRNA and protein-based COVID-19 vaccine platforms...
10.
Voysey M, Flaxman A, Aboagye J, Aley P, Belij-Rammerstorfer S, Bibi S, et al.
Clin Exp Immunol
. 2023 Feb;
211(3):280-287.
PMID: 36729167
The trajectory of immune responses following the primary dose series determines the decline in vaccine effectiveness over time. Here we report on maintenance of immune responses during the year following...